BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Myriad Genetics, Inc. (MYGN) Supreme Court Case Has Promising Outcome for Immunomic Therapeutics


6/20/2013 9:47:45 AM

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

ROCKVILLE, Md.--(BUSINESS WIRE)--In a case involving leading molecular diagnostic company Myriad Genetics, the Supreme Court ruled unanimously last Thursday that human genes cannot be patented. The Court invalidated Myriad’s patents on two breast cancer genes because Myriad’s patented genes were found in nature; therefore, Myriad had not invented anything when it received patents for the genes in 1996. However, the court did determine that manipulations of genes and DNA remain patentable, upholding patents for cDNA. Immunomic Therapeutics, Inc. (ITI) is pleased to announce that the Court’s decision does not affect the Company’s intellectual property including its issued patents covering the LAMP Technology Platform. In addition to having no direct impact on LAMP vaccines, including all work to date, the ruling gives the company access to data that promises to serve ITI well moving forward. ITI’s Lysosome-Associated Membrane Protein (LAMP) patents do not directly claim the LAMP genes in the primary claims, instead claiming both the four-amino-acid sequence that targets the lysosome and the luminal domain of LAMP linked to other DNA sequences. None of the constructs used by ITI could be found in Nature, and as such, the Court’s ruling will not hinder ITI’s future innovations in plasmid vaccines.

Help employers find you! Check out all the jobs and post your resume.


Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES